文献速递主动脉疾病

编辑精选——用于完整腹主动脉瘤腔内修复的主要当代内移植物装置结局比较

Editor's Choice - Comparison of Outcomes for Major Contemporary Endograft Devices Used for Endovascular Repair of Intact Abdominal Aortic Aneurysms.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2022-11-09

该回顾性队列研究链接澳大利亚新南威尔士州临床注册与行政数据,纳入2010至2019年因完整腹主动脉瘤行EVAR的2874例患者,比较Cook、Medtronic和Gore标准装置的全因死亡、继发破裂和二次干预率。中位随访4.1年,各装置死亡率与继发破裂率无统计学显著差异,但Medtronic装置后继动脉瘤修复率显著高于Cook装置(HR 1.57,95%CI 1.02-2.47)。

要点

  • 各主要内移植物装置的全因死亡率与继发破裂率无统计学显著差异。
  • Medtronic装置后继动脉瘤修复率显著高于Cook装置(HR 1.57,95%CI 1.02-2.47)。
  • Gore装置后继动脉瘤修复率与Cook装置比较未达统计学显著(HR 1.73,95%CI 0.94-3.18)。

核心结论

  • 主要内移植物装置具有相似的总体长期安全性特征,但某些装置的二次干预率可能存在差异,可能反映内移植物耐久性或基于动脉瘤解剖的患者选择差异,需要持续比较评估以指导治疗决策。

研究设计与样本

  • 回顾性队列研究,链接澳大利亚新南威尔士州临床注册(Australasian Vascular Audit)与全付费方行政数据,纳入2010至2019年因完整腹主动脉瘤行EVAR的患者共2874例,中位随访4.1年(最长9.5年)。
  • 比较Cook、Medtronic和Gore标准装置,采用逆概率治疗加权比例风险模型和竞争风险回归调整患者、临床和动脉瘤特征,以Cook装置为参照。

主要发现

  • 不同装置的全因死亡率相似,范围在每100人年7.0至7.3之间。
  • 不同装置的继发破裂率无统计学显著差异,范围在每100人年0.4至0.5之间。
  • 接受Medtronic和Gore装置的患者后继动脉瘤修复粗率(每100人年1.5)倾向于高于接受Cook装置的患者(每100人年0.8)。
  • 调整分析中该发现仍存在,但仅Medtronic装置具有统计学显著性(HR 1.57,95%CI 1.02-2.47),Gore装置未达统计学显著(HR 1.73,95%CI 0.94-3.18)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare rates of mortality, rupture, and secondary intervention following endovascular repair (EVAR) of intact abdominal aortic aneurysms (AAA) using contemporary endograft devices from three major manufacturers. METHODS: This was a retrospective cohort study using linked clinical registry (Australasian Vascular Audit) and all payer administrative data. Patients undergoing EVAR for intact AAA between 2010 and 2019 in New South Wales, Australia were identified. Rates of all cause death, secondary rupture, and secondary intervention (subsequent aneurysm repair; other secondary aortic intervention) were compared for patients treated with Cook, Medtronic, and Gore standard devices. Inverse probability of treatment weighted proportional hazards and competing risk regression were used to adjust for patient, clinical, and aneurysm characteristics, using Cook as the referent device. RESULTS: This study identified 2 874 eligible EVAR patients, with a median follow up of 4.1 (maximum 9.5) years. Mortality rates were similar for patients receiving different devices (ranging between 7.0 and 7.3 per 100 person years). There was no statistically significant difference between devices in secondary rupture rates, which ranged between 0.4 and 0.5 per 100 person years. Patients receiving Medtronic and Gore devices tended to have higher crude rates of subsequent aneurysm repair (1.5 per 100 person years) than patients receiving Cook devices (0.8 per 100 person years). This finding remained in the adjusted analysis, but was only statistically significant for Medtronic devices (HR 1.57, 95% CI 1.02 - 2.47; HR 1.73, 95% CI 0.94 - 3.18, respectively). CONCLUSION: Major endograft devices have similar overall long term safety profiles. However, there may be differences in rates of secondary intervention for some devices. This may reflect endograft durability, or patient selection for different devices based on aneurysm anatomy. Continuous comparative assessments are needed to guide evidence for treatment decisions across the range of available devices.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Falster MO, Garland SK, Jorm LR, et al. Editor's Choice - Comparison of Outcomes for Major Contemporary Endograft Devices Used for Endovascular Repair of Intact Abdominal Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2022. PMID: 36334901. doi:10.1016/j.ejvs.2022.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。